BioNTech BNTX
GermanyHealthcare · BiotechnologyUSD
115.86 USD (+21.6%)
20 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
BioNTech SE is a German biotechnology company that develops and commercializes messenger RNA (mRNA) therapies and vaccines, best known for its COVID-19 vaccine developed with Pfizer.
Key points
from its scores- ✕Weak growth0.0
- ✕Little or no dividend1.5
- ✕Poor share-price trend2.1
AI analysis
bottom line, main risk, context and newsHold only with a long-term horizon and high risk tolerance; the value depends on its mRNA pipeline generating revenue before cash is depleted.
BioNTech is going through a difficult transition: revenue fell 59.5% as COVID-19 vaccine demand dried up, operating margin is -806.63% and ROIC is -109.39%, although it maintains a solid liquidity ratio of 7.85 that gives it room to fund its pipeline.
The main risk is dependence on a not-yet-commercialized mRNA pipeline: if clinical trials fail or are delayed, the company could burn through its cash without reaching a new revenue source.
Context and risks
BioNTech has no recent relevant news and its biotech profile with net cash (liquidity 7.85) shields it from the rise in interest rates and commodity volatility. The main risk is purely operational: the 59.5% revenue decline due to the end of COVID-19 vaccine demand and an operating margin of -806.63% reflecting deep losses.
Is BioNTech stock cheap or expensive?
at the analysis dateOn Price / sales, it trades 136% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 1.1 | 4.1 | −73% |
| Price / sales | 8.1 | 3.4 | +136% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 4.8 out of 10 (median for Healthcare: 4.7).
Average analyst target: 115.86 USD, +21.6% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 3.3 (sector 5.5), Growth 0.0 (sector 6.6).
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- −17.2
- EV / EBITDA
- −5.9
- Price / book
- 1.1
- Price / sales
- 8.1
- PEG
- 0.05
- Market cap
- 23.9B USD
- Enterprise value
- 8.2B EUR
Profitability
- ROE
- −9.3%
- ROA
- −5.4%
- ROIC (approx.)
- −109.4%
- Gross margin
- 76.6%
- Operating margin
- −806.6%
- Net margin
- −63.6%
- Free cash flow
- −249.6M EUR
- FCF yield
- −1.2%
Solvency
- Total debt
- 316.1M EUR
- Net debt
- −13.1B EUR
- Cash
- 13.5B EUR
- EBITDA
- −1.4B EUR
- Net debt / EBITDA
- 9.52
- Debt / equity
- 1.78
- Current ratio
- 7.85
- Quick ratio
- 7.03
Growth
- Revenue growth
- −59.5%
- EPS (TTM)
- −7.83 USD
- EPS (forward)
- −5.53 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 1.25
- Analyst consensus
- Buy (20)
- Target price
- 115.86 USD
- 52-week range
- 79.52 – 124.00
Recent news
All BNTX news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about BioNTech
Is BioNTech stock cheap or expensive?
On Price / sales, it trades 136% above the Healthcare median. Valuation score: 4.8 out of 10 (median for Healthcare: 4.7). Average analyst target: 115.86 USD, +21.6% versus the price. This is not investment advice.
What score does BioNTech get on MeridIAn Screener?
It scores 3.1 out of 10, rank 2,075 of 2,130 (better than 2% of the companies analysed). Its strongest category is Risk & Context (5.2) and its weakest, Growth (0.0). Analysis of 08/10/2026.
How much is BioNTech worth on the stock market?
Its market capitalisation is 23.9B USD and its enterprise value, debt included, is 8.2B USD.
How much debt does BioNTech have?
It has more cash than debt: net cash of 13.1B EUR.
Does BioNTech pay a dividend?
It pays no dividend, or almost none.
How has BioNTech stock performed over the last year?
It has fallen 6.7% over the last year, excluding dividends. Over the last 52 weeks it has traded between 79.52 and 124.00 USD. Past performance does not guarantee future results.
What do analysts think of BioNTech?
20 analysts cover it; their average recommendation is “Buy” and their average target is 115.86 USD (+21.6% versus the price). It is an estimate, not market data.